# Lormalzi is a once-monthly amyloid plaque-targeting therapy approved for patients with mild cognitive impairment or mild dementia due to Alzheimer's disease.

*biotech · news · 2026-05-13 · NDTV.com*

## Key points

- Eli Lilly launched Lormalzi (donanemab), India's first once-monthly amyloid plaque-targeting Alzheimer's therapy.
- Lormalzi costs Rs91,688 per 350 mg vial and is approved for early Alzheimer's with confirmed amyloid pathology.
- Blood-based biomarker tests like pTau217 and beta-amyloid 1-42 now enable over 90% accuracy for amyloid detection in India.
- In India, Lormalzi treatment typically lasts 18 months due to limited access to amyloid PET imaging.

**Companies:** Eli Lilly and Company
**Countries:** India, United States of America, United Kingdom, European Union, Japan

[Read the full story on NDTV.com](https://www.ndtv.com/health/eli-lilly-launches-alzheimers-drug-lormalzi-priced-at-rs91688-per-vial-in-india-11489362)

---

Canonical: https://newsio.io/n/f5e56ff8-c580-4526-b90e-95554f6597f1/lormalzi-is-a-once-monthly-amyloid-plaque-targeting-therapy-approved-for-patient
Summarized by Newsio from NDTV.com. https://newsio.io/how-it-works